Anti-CD13 antibody [R3-63] (FITC) (ab33486)
- Product nameAnti-CD13 antibody [R3-63] (FITC)See all CD13 primary antibodies ...
- DescriptionRat monoclonal [R3-63] to CD13 (FITC)
- ConjugationFITC. Ex: 493nm, Em: 528nm
- SpecificityRecognizes mouse aminopeptidase N (APN), a cell surface protein homologous with human CD13.
- Tested applicationsFlow Cyt more details
- Species reactivityReacts with: Mouse
Intestinal CD13 (Mouse)
- Storage instructionsStore at +4°C.
- Storage bufferPreservative: 0.09% Sodium Azide
Constituents: 1% BSA, PBS, pH 7.4
- Concentration information loading...
- PurityProtein G purified
- Purification notesPurified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Primary antibody notes In the mouse, CD13 is a non-covalently linked homodimer of approximately 150kD subunits expressed by a variety of cells including monocytes, macrophages, dendritic cell and veiled cells. Clone R3-63 has been reported to block mouse APN enzyme activity.
- Clonality Monoclonal
- Clone numberR3-63
- Research Areas
Our Abpromise guarantee covers the use of ab33486 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
- FunctionBroad specificity aminopeptidase. Plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. May play a critical role in the pathogenesis of cholesterol gallstone disease. May be involved in the metabolism of regulatory peptides of diverse cell types including small intestinal and tubular epithelial cells, macrophages, granulocytes and synaptic membranes from the CNS. Found to cleave antigen peptides bound to major histocompatibility complex class II molecules of presenting cells and to degrade neurotransmitters at synaptic junctions. Is also implicated as a regulator of IL-8 bioavailability in the endometrium, and therefore may contribute to the regulation of angiogenesis. Is used as a marker for acute myeloid leukemia and plays a role in tumor invasion. In case of human coronavirus 229E (HCoV-229E) infection, serves as receptor for HCoV-229E spike glycoprotein. Mediates as well human cytomegalovirus (HCMV) infection.
- Tissue specificityExpressed in epithelial cells of the kidney, intestine, and respiratory tract; granulocytes, monocytes, fibroblasts, endothelial cells, cerebral pericytes at the blood-brain barrier, synaptic membranes of cells in the CNS. Also expressed in endometrial stromal cells, but not in the endometrial glandular cells. Found in the vasculature of tissues that undergo angiogenesis and in malignant gliomas and lymph node metastases from multiple tumor types but not in blood vessels of normal tissues. A soluble form has been found in plasma. It is found to be elevated in plasma and effusions of cancer patients.
- Sequence similaritiesBelongs to the peptidase M1 family.
- DomainAmino acids 260-353 are essential to mediate susceptibility to infection with HCoV-229E (in porcine/human chimeric studies) and more specifically amino acids 288-295 (mutagenesis studies).
N- and O-glycosylated.
May undergo proteolysis and give rise to a soluble form.
- Cellular localizationCell membrane. Cytoplasm > cytosol. A soluble form has also been detected.
- Alanyl (membrane) aminopeptidase antibody
- Alanyl aminopeptidase antibody
- Alanyl membrane aminopeptidase antibody
- Aminopeptidase M antibody
- Aminopeptidase N antibody
- AMPN_HUMAN antibody
- ANPEP antibody
- AP M antibody
- AP N antibody
- AP-M antibody
- AP-N antibody
- APN antibody
- CD 13 antibody
- CD13 antibody
- CD13 antigen antibody
- gp150 antibody
- hAPN antibody
- Lap 1 antibody
- Lap1 antibody
- Microsomal aminopeptidase antibody
- Myeloid plasma membrane glycoprotein CD13 antibody
- p150 antibody
- PEPN antibody
References for Anti-CD13 antibody [R3-63] (FITC) (ab33486)
ab33486 has not yet been referenced specifically in any publications.